Psychosomatics 43:451-455, December 2002
© 2002 The Academy of Psychosomatic Medicine
Does a Preexisting Anxiety Disorder Predict Response to Paroxetine in Irritable Bowel Syndrome?
Prakash S. Masand, M.D.,
Sanjay Gupta, M.D.,
Thomas L. Schwartz, M.D.,
David Kaplan, M.D.,
Subhdeep Virk, M.D.,
Ahmad Hameed, M.D., and
Kari Lockwood, R.N.
Presented in part at the 154th annual meeting of the American Psychiatric Association, New Orleans, May 5–10, 2001. Received September 6, 2001; revision received April 5, 2002; accepted April 16, 2002. From the Department of Psychiatry, Duke University Medical Center; Olean General Hospital, Olean, N.Y.; State University of New York Upstate Medical University, Syracuse, N.Y.; and Syracuse Gastroenterological Associates, Syracuse, N.Y. Address reprint requests to Dr. Masand, Department of Psychiatary, Duke University Medical Center, Duke South Box 3391, Durham, NC 27710; masan001{at}mc.duke.edu (e-mail).
Irritable bowel syndrome (IBS) is the most common disorder in patients seen by gastroenterologists. Twenty subjects with IBS diagnosed with the Rome criteria were treated for 12 weeks with 20–40 mg/day of paroxetine (mean dose=31 mg/day). At baseline, 10 patients had a lifetime history of an anxiety disorder, and 10 patients did not have such a history. Both groups had similar improvement in abdominal pain, constipation, diarrhea, incomplete emptying, and bloating/ abdominal distension. Paroxetine was very well tolerated.
Key Words: Irritable bowel syndrome • Anxiety disorder • paroxetine • Comorbidity • SSRIs
Get information about faster international access.
Privacy Policy
Copyright © 2002
Academy of Psychosomatic Medicine.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
